Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BAX 
Baxter International Inc (BAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: BAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
18 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $29
1 Year Target Price $29
| 4 | Strong Buy |
| 2 | Buy |
| 11 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.94% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.26B USD | Price to earnings Ratio - | 1Y Target Price 29 |
Price to earnings Ratio - | 1Y Target Price 29 | ||
Volume (30-day avg) 18 | Beta 0.6 | 52 Weeks Range 21.18 - 38.83 | Updated Date 09/17/2025 |
52 Weeks Range 21.18 - 38.83 | Updated Date 09/17/2025 | ||
Dividends yield (FY) 3.36% | Basic EPS (TTM) -0.48 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -1.42% | Operating Margin (TTM) 15.45% |
Management Effectiveness
Return on Assets (TTM) 2.73% | Return on Equity (TTM) -3.21% |
Valuation
Trailing PE - | Forward PE 9.55 | Enterprise Value 20299134726 | Price to Sales(TTM) 1.13 |
Enterprise Value 20299134726 | Price to Sales(TTM) 1.13 | ||
Enterprise Value to Revenue 1.86 | Enterprise Value to EBITDA 19.61 | Shares Outstanding 513620992 | Shares Floating 511463853 |
Shares Outstanding 513620992 | Shares Floating 511463853 | ||
Percent Insiders 0.37 | Percent Institutions 102.38 |
Upturn AI SWOT
Baxter International Inc
Company Overview
History and Background
Baxter International Inc. was founded in 1931 as Don Baxter Intravenous Products Corporation. It pioneered the commercial production of prepared intravenous solutions and has evolved into a global healthcare company.
Core Business Areas
- Medical Products and Therapies: This segment provides a range of products and therapies used to treat kidney disease, including dialysis products, therapies for acute kidney injury, and other related products. It also includes other medical devices and therapies.
- Pharmaceuticals: This segment produces premixed injectable drugs and infusion systems, including products used in hospitals and clinics.
- Acute Therapies: Acute Therapies include products for medication delivery, renal and respiratory therapies.
Leadership and Structure
Jose E. Almeida serves as the Chairman, President, and Chief Executive Officer. The company has a typical corporate structure with various departments reporting to the CEO and executive leadership team.
Top Products and Market Share
Key Offerings
- Peritoneal Dialysis (PD) Solutions: Baxter is a leading provider of PD solutions, capturing a significant market share in the renal care space. Competitors include Fresenius Medical Care and DaVita.
- Intravenous (IV) Solutions: Baxter offers a wide array of IV solutions for hydration and medication delivery. Competitors include B. Braun and ICU Medical.
- Infusion Pumps: Baxter produces infusion pumps used to deliver fluids and medications. Key competitors include Becton Dickinson (BD), ICU Medical.
Market Dynamics
Industry Overview
The healthcare industry is characterized by innovation, regulatory scrutiny, and increasing demand due to an aging population and chronic diseases.
Positioning
Baxter is a global leader in renal care and hospital products, with a strong brand reputation and established distribution networks. Its competitive advantages include its breadth of product offerings and global reach.
Total Addressable Market (TAM)
The global market for renal dialysis is projected to reach billions of dollars. Baxter is well positioned to capture a significant share of this market given its broad portfolio and geographical presence.
Upturn SWOT Analysis
Strengths
- Global presence and distribution network
- Broad product portfolio
- Strong brand reputation
- Established relationships with healthcare providers
- Innovation in renal care
Weaknesses
- Exposure to regulatory risks
- Dependence on hospital spending
- Product recalls
- Debt burden
Opportunities
- Growth in emerging markets
- Development of new therapies and technologies
- Strategic acquisitions
- Partnerships with healthcare providers
- Increased demand for home dialysis
Threats
- Intense competition
- Pricing pressures
- Changes in healthcare regulations
- Economic downturns
- Product liability claims
Competitors and Market Share
Key Competitors
- FMS
- DVA
- BDX
- ICU
Competitive Landscape
Baxter faces intense competition from established players and generic manufacturers. Its success depends on innovation, cost control, and effective marketing.
Major Acquisitions
Hillrom
- Year: 2021
- Acquisition Price (USD millions): 10500
- Strategic Rationale: Expanded Baxter's connected care solutions portfolio and strengthened its position in the hospital and home settings.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been moderate, with fluctuations due to economic conditions and strategic decisions.
Future Projections: Analyst estimates vary, but generally project modest revenue growth driven by new products and emerging markets.
Recent Initiatives: Baxter has focused on strategic acquisitions and partnerships to expand its product portfolio and market reach.
Summary
Baxter International is a major player in the healthcare industry, particularly in renal care and hospital products. Its strengths lie in its global reach and diverse product portfolio. However, it faces challenges from competition, regulatory pressures, and debt. Successful innovation and strategic initiatives are crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data may be delayed and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Baxter International Inc
Exchange NYSE | Headquaters Deerfield, IL, United States | ||
IPO Launch date 1981-10-27 | CEO, President & Director Mr. Andrew P. Hider | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 38000 | Website https://www.baxter.com |
Full time employees 38000 | Website https://www.baxter.com | ||
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.